COMMUNIQUÉS West-GlobeNewswire

Belite Bio to Participate in Four Upcoming Investor Conferences
23/04/2026
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Nanox Signs Distribution Agreement with Radiology Oncology Systems to Expand Nanox.ARC Adoption in the United States
23/04/2026
Expands Nanox’s growing network of U.S. distribution partnerships PETAH TIKVA, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical [...]
Noom Health’s SmartRx Program on Track to Cut Employer’s GLP-1 Spend by Nearly 80%
23/04/2026
Early data from first participating employer show that Smart Rx can save organizations millions by bypassing traditional PBMs to deliver brand-name GLP-1 medications NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Noom [...]
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
23/04/2026
- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study [...]
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
23/04/2026
CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
23/04/2026
ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population [...]
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
23/04/2026
STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, [...]
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
23/04/2026
WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet [...]
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
23/04/2026
CUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to [...]
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
23/04/2026
Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of psychedelics. As science, policy [...]
Verano Founder and Chief Executive Officer George Archos Celebrates Historic Announcement Confirming Cannabis Rescheduling to Schedule III
23/04/2026
Verano’s active operations span 13 states, comprised of 1 6 2 dispensaries operating under the Zen Leaf ™ and MÜV ™ retail banners, and 1 4 cultivation and processing facilities with more than 1.1 million square feet of [...]
Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
23/04/2026
Tilray Medical Poised to Accelerate U.S. Medical Cannabis Access for Patients NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.  (“Tilray”, “our”, “we” or the “Company”) (NASDAQ: TLRY; TSX: TLRY), a [...]
SS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026
23/04/2026
Innovations under development by Company include the SSi Vimana Aero, SSi Avtara and SSi Operion FORT LAUDERDALE, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS [...]
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
23/04/2026
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need. The trial demonstrated a statistically [...]
Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call
23/04/2026
ATLANTA, April 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 14 [...]
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
23/04/2026
Appoints Leading Oncologist Professor Susana Banerjee of The Royal Marsden as Chief Investigator CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing [...]
Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé
23/04/2026
Nomme la professeure Susana Banerjee, éminente oncologue du Royal Marsden, en tant que chercheuse principale CAMBRIDGE, Royaume-Uni et MONTRÉAL, 23 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société biotechnologique [...]
Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms
23/04/2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the company’s first-in- [...]
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
23/04/2026
STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

Pages